4.2 Antibody Detection, Identification & Compatibility Testing

The Antiglobulin Test (Coombs Test)

The antiglobulin test is the cornerstone of immunohematology. It utilizes Anti-Human Globulin (AHG) reagent to detect human IgG antibodies and/or complement components that have sensitized (attached to) red blood cells but have not caused direct agglutination. IgG antibodies are typically "incomplete" agglutinins; they bind to red cell antigens but are too small to bridge the gap between adjacent cells to cause visible lattice formation (unlike the much larger IgM pentamers). The AHG reagent, being a large IgM antibody directed against human IgG or complement, bridges this gap, resulting in visible agglutination.

Direct Antiglobulin Test (DAT)

The DAT detects in vivo sensitization of red blood cells (antibodies attached to the cells inside the patient's body). It is performed by taking the patient's red cells, washing them thoroughly to remove unbound serum proteins, and adding AHG reagent.

Clinical Applications of the DAT:

• Hemolytic Disease of the Fetus and Newborn (HDFN): Detecting maternal IgG antibodies coating fetal red cells.
• Hemolytic Transfusion Reactions (HTR): Detecting recipient antibodies coating transfused donor red cells.
• Autoimmune Hemolytic Anemia (AIHA): Detecting autoantibodies coating the patient's own red cells.
• Drug-Induced Hemolytic Anemia: Detecting drug-antibody complexes binding to red cells.

Indirect Antiglobulin Test (IAT)

The IAT detects in vitro sensitization (antibodies in the serum/plasma that attach to reagent red cells during laboratory incubation). It requires incubating the patient's serum with known reagent red cells, washing, and then adding AHG reagent.

Clinical Applications of the IAT:

• Antibody Screening: Detecting unexpected alloantibodies in patient serum.
• Antibody Identification: Identifying the specificity of the alloantibody using a panel of characterized red cells.
• Crossmatching: Testing patient serum against donor red cells to ensure compatibility.
• Antigen Typing: Using known antisera to determine the patient's extended red cell phenotype.

Antibody Screening and Identification

The antibody screen uses 2 or 3 Group O screening cells with known, characterized antigen profiles. If the screen is positive, an antibody identification panel (typically 11-16 Group O cells) must be performed. The Group O cells are essential to prevent interference from naturally occurring anti-A and anti-B in the patient's serum.

Exclusion Rules and the Dosage Effect

Antibody identification relies heavily on the process of elimination. If a patient's serum does not react with a panel cell, it is logically assumed that the patient does not have antibodies against the antigens present on that specific cell. We then "cross out" or "rule out" those antigens from the list of possibilities.

The Rule of Exclusion: To confidently rule out an antibody, the corresponding antigen must be present on a panel cell that gives a completely negative reaction across all phases of testing (Immediate Spin, 37°C, and AHG).

The Dosage Effect: This is a crucial concept. Some antibodies react more strongly with red cells from homozygous individuals (e.g., inherit genes for $Jk^a/Jk^a$, possessing a double dose of the antigen) than with red cells from heterozygous individuals (e.g., $Jk^a/Jk^b$, possessing a single dose of Jka and a single dose of Jkb). Antibodies that commonly exhibit dosage include those in the Rh (C, c, E, e), Kidd (Jka, Jkb), Duffy (Fya, Fyb), and MNS (M, N, S, s) systems.

Impact on Rule Outs: Because of the dosage effect, a weak antibody might react with a homozygous cell (double dose) but fail to react with a heterozygous cell (single dose). If you use a non-reacting heterozygous cell to rule out an antibody, you might falsely eliminate it, missing a clinically significant antibody that could harm the patient. Therefore, exclusion must always be performed using homozygous cells for antigens known to exhibit dosage. The only common exception is the K antigen, where heterozygous K+k+ cells are often accepted for rule-out due to the extreme rarity of homozygous K+K+ cells.

System-Specific Clinical Characteristics

Understanding the unique behaviors of specific blood group system antibodies is vital for accurate identification and predicting clinical outcomes.

The Kidd System (Jka, Jkb)

• Antibody Characteristics: Kidd antibodies are notorious in blood banking. They are IgG, react optimally at the AHG phase, and commonly show strong dosage. They are unique because they often activate complement efficiently.
• Clinical Danger: They are the classic culprits for Delayed Hemolytic Transfusion Reactions (DHTRs). A patient may be immunized from a past transfusion or pregnancy, but over time, Kidd antibody titers drop rapidly, often falling below the detectable limit of a standard antibody screen. When re-exposed via transfusion, the patient mounts a massive anamnestic (memory) response, destroying the transfused cells days after the seemingly compatible transfusion.
• Enzyme Effect: Kidd antigens are enhanced by proteolytic enzymes (like ficin or papain), making enzyme panels very useful for identifying weak Kidd antibodies.

The Duffy System (Fya, Fyb)

• Antibody Characteristics: Duffy antibodies are IgG and react at the AHG phase. They also frequently exhibit dosage.
• Enzyme Effect: Duffy antigens are completely destroyed by proteolytic enzymes. If an antibody reacts at AHG but the reaction disappears when testing with enzyme-treated cells, a Duffy antibody is highly suspected.
• Malaria Resistance: The Duffy antigens serve as the receptor for the malarial parasite Plasmodium vivax. Individuals who are Fy(a-b-) lack these receptors and are naturally resistant to P. vivax infection. This null phenotype is extremely common (over 68%) in populations of West African descent due to evolutionary selection pressure.

The MNS System (M, N, S, s, U)

• Anti-M and Anti-N: These are typically naturally occurring cold agglutinins (IgM) that react at room temperature and are often clinically insignificant. They exhibit strong dosage. The M and N antigens are destroyed by enzymes.
• Anti-S, Anti-s, and Anti-U: Unlike M and N, antibodies to S, s, and U are typically IgG, react at 37°C and AHG, and are highly clinically significant, capable of causing severe hemolytic transfusion reactions and HDFN. The U antigen is a high-incidence antigen found on almost all human red cells; individuals who are S-s- are also U-negative (a rare phenotype found mostly in individuals of African descent) and can form anti-U.

Compatibility Testing (Crossmatching)

The crossmatch is the final, essential check before transfusion. Its primary purpose is to prevent life-threatening acute hemolytic transfusion reactions and maximize the in vivo survival of transfused red cells.

Major Crossmatch: Tests the recipient's serum/plasma against the donor's red cells.

• Immediate Spin (IS) Crossmatch: Used if the patient has a negative antibody screen and no history of clinically significant antibodies. It only detects ABO incompatibility. The donor cells and patient serum are mixed, centrifuged, and read for agglutination immediately.
• Full (AHG) Crossmatch: Required if the patient has a positive antibody screen or a history of clinically significant antibodies. It involves incubation at 37°C and testing through the AHG phase to ensure the donor cells lack the antigen corresponding to the patient's antibody. Antigen-negative units must be selected for the crossmatch.
• Electronic (Computer) Crossmatch: Can replace the IS crossmatch if strict computer system validations are met, the patient has a negative antibody screen and history, and the patient has two separate, matching ABO/Rh typings on file.